March 27, 2018

At the extraordinary general meeting of the Pharmstandard JSC shareholders, taking place on the 15^th of March, 2018, it was decided to reorganize the company by separating out Vektor – BioPharm, a new joint-stock company. The process of assets formation of the newly created company is mainly carried out at the expense of non-core assets and monetary funds of Pharmstandard JSC. At the same time, investment activity is defined as the main course of action for Vektor – BioPharm. The registration of a new legal entity is set to July this year.

"The allocation non-core assets will allow Pharmstandard to focus its efforts on the main line of business – production of pharmaceuticals," said Grigoriy Potapov, Director General of Pharmstandard JSC.

Since Egor Kulkov has just before lost his beneficiary status of Pharmstandard JSC as a result of changes in members of Augment Investments Limited, the controlling shareholder of Pharmstandard JSC, Viktor Kharitonin, following the reorganization results, will be the sole beneficiary of both companies.